Prediabetes: Diagnosis, evaluation of chronic complications, and treatment;Pré-diabetes: Diagnóstico, avaliação de complicações crônicas e tratamento

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 56, Issue 5, 2012, Pages 275-284

  de Souza, Camila Furtado ^a   Gross, Jorge Luiz ^a   Gerchman, Fernando ^a   Leitão, Cristiane Bauermann ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cardiovascular disease; Diabetes mellitus; Microvascular complications; Prediabetes; Prevention

Indexed keywords

CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETES MELLITUS; GLUCOSE INTOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; MICROVESSELS; PREDIABETIC STATE; RISK FACTORS;

EID: 84865396071     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302012000500001     Document Type: Review

References (59)

1. Standards of Medical Care in Diabetes - 2011. Position Statement/American Diabetes Association. Diabetes Care. 2011;33(S1):S11-61.
2. Caderno de Atenção Básica n° 16: diabetes mellitus. Ministério da Saúde. Brasília, 2006.
3. Dall T, Mann SE, Zhang Y, Martin J, Chen Y, Hogan P. Economic costs of diabetes in the U.S. in 2007. American Diabetes Association. Diabetes Care. 2008;31:596-615.
4. Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CDA, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in Dutch population: The HOORN Study. JAMA. 2001;285(16):2109-13.
5. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
6. Genuth S, ALberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-7.
7. Gross JL, Silveiro SP, Camargo JL, Reichelt AJ, Azevedo MJ. Diabetes melito: diagnóstico, classificação e avaliação do controle glicêmico. Arq Bras Endocrinol Metab. 2002;46(1):16-26.
8. The International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-34.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;33(S1):S62-9.
10. Bennet CM, Guo M, Dharmage SC. HbA1c as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med. 2007;24:333-43.
11. Diretrizes da Sociedade Brasileira de Diabetes 2009. Sociedade Brasileira de Diabetes. 3a edição. São Paulo, 2009.
12. Gomes-Perez FJ, Aguilar-Salinas CA, Almeda-Valdes P, Cuevas-Ramos D, Garber IL, Rull JA. HbA1c for the diagnosis of diabetes mellitus in a developing country. A position Article. Arch Med Res. 2010;41:302-8.
13. Cavagnolli G, Gross JL, Camargo JL. HbA1c, glicemia de jejum e teste oral de tolerância à glicose no diagnóstico de diabetes: que teste usar? Rev HCPA. 2010;30(4):315-20.
14. García-Alcalá H, Ruiz-Argüelles A, Cedillo-Carvallo B. Effect of the method to mesure levels of glycated hemoglobin on individual clinical decisions comparison of an immunoassay with high-performance liquid chromatography. Am J Clin Pathol. 2009;132:332-5.
15. James C, Bullard KMK, Rolka DB, Geiss LS, Williams DE, Cowie CC, et al. Implications of Alternative Definitions of Prediabetes for Prevalence in U.S. Adults. Diabetes Care. 2011;34:387-91.
16. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753-9.
17. Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic over-view and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78:305-12.
18. Pankow JS, Kwan DK, Duncan BB, Schmidt MI, Couper DJ, Golden S, et al. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007;30:325-31.
19. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-53.
20. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association criteria - The DECODE study group. Lancet. 1999;354:617-21.
21. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004;25:1990-7.
22. Tominaga M, Eguchi H, Manaka H, Igarashi K. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22:920-4.
23. Shaw JE, Zimmet PZ, Hodge AM, Courten M, Dowse GK, Chitson P, et al. Impaired fasting glucose: how low should it go? Diabetes Care. 2000;23:34-9.
24. Lim SC, Tai ES, Tan BY, Chew SK, Tan CE. Cardiovascular risk profile in individuals with borderline glicemia. Diabetes Care. 2000;23:278-82.
25. Wen CP, Cheng TYD, Tsai SP, Hsu HL, Wang SL. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care. 2005;28:2756-61.
26. Barr ELM, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, an Lifestyle Study (AusDiab). Circulation. 2007;116:151-7.
27. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA, Dekker JM. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn Study. Diabetes Care. 2007;30:332-6.
28. Ford ES, Zaho G, Li C. Prediabetes and the risk for cardiovascular disease. A systematic review of the evidence. JACC. 2010;55:1310-7.
29. Singleton JR, Smith AG, Russel JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes. 2003;52:2867-73.
30. Franklin GM, Kahn LB, Bender J, Marshall JA, Hamman F. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol. 1990;131:633-43.
31. Nelson RG, Kunzelman CL, Pettitt DJ, Saad MF, Bennett PH, Knowler WC. Albuminuria in Type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima indians. Diabetologia. 1989;32:870-86.
32. Meigs JB, Dágostinho RB, Nathan DM, Rifai N, Wilson PW. Longitudinal Association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care. 2002;25:977-83.
33. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabetes Prevention Program Research Group. Diabetic Medicine. 2007;24:137-44.
34. Nagi DK, Pettitt DJ, Bennett PH, Klein R, Knowler WC. Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and NIIDM. Diabetic Medicine. 1997;14(6):449-56.
35. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. The Finish Diabetes Prevention Study. N Engl J Med. 2002;344:1343-50.
36. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-9.
37. DPP Research Group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
38. DPP Research Group: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677-86.
39. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-44.
40. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783-9.
41. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDDP-1). Diabetologia. 2006;49:289-97.
42. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67:152-62.
43. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359:2072-7.
44. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku, K. Voglibose Ph-3 Study Group: Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607-14.
45. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61.
46. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096-105.
47. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: effect of ramipril on the incidence of diabetes. N Eng J Med. 2006;355:1551-62.
48. DeFronzo RA, for ACT NOW Study Group. ACTos NOW Study for the Prevention of Diabetes (ACT NOW) Study. Late-breaking abstract presented at 68th Annual Scientific Sessions of the American Diabetes Association, 6 June 2008, San Francisco, CA.
49. The NAVIGATOR Study Group: effect of valsartan on the incidence of diabetes and cardiovascular events. N Eng J Med. 2010;362:1477-90.
50. The NAVIGATOR Study Group: effect of nateglinide on the incidence of diabetes and cardiovascular events. N Eng J Med. 2010;362:1477-90.
51. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomized controlled study. Lancet. 2010;376:103-11.
52. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, et al. HOPE Study Investigators: Ramipril and the development of diabetes. JAMA. 2001;286:1882-5.
53. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al.; for the LIFE study group: risk of new-onset diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension study. J Hypertens. 2002;20:1879-86.
54. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-62.
55. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, et al. Heart and Estrogen/progestin Replacement Study: glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1-9.
56. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA. 2003;290:486-94.
57. Sjostrom L. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-93.
58. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-23.
59. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Blommgarden ZT, Fonseca V, et al. Prediabetes Consensus Statement. Endocr Pract. 2008;14:933-45.